Revvity Q2 EPS of $1.18 beat the $1.14 estimate; revenue rose to $720.28 million, topping $710.71 million consensus. FY25 EPS guidance trimmed to $4.85-$4.95 from $4.90-$5.00 due to China DRG policy headwinds. Missed the rally? Learn exactly where the next leaders are emerging here. Revvity Inc.

Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.

Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.

Beyond analysts' top-and-bottom-line estimates for Revvity (RVTY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.